ClinicalTrials.gg
CompletedNCT06195150ITHORinVHLUpdated Oct 16, 2026

Overtaking Intra and Inter Tumoral Heterogeneity In Von Hippel-Lindau Related Renal Cancer

An observational study in Clear Cell Renal Cell Carcinoma and VHL Syndrome, sponsored by IRCCS San Raffaele. Completed at 1 site in Italy. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by IRCCS San Raffaele · Observational

How we know

Updated Oct 16, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
3
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 154 studies in Carcinoma, Renal Cell with a site in Italy — 28 open to participants now, 47 under way, 15 of them phase 3. Carcinoma, Renal Cell · Italy.

Enrollment
30th of 30
3 · median 213
Started
2023
with 8 others
Observational
30 of 154
13 open now
Registered
132nd of 154
by date

Among the 154 studies in Carcinoma, Renal Cell with a site in Italy, this one is the 30th largest by enrollment of the 30 observational ones that give a count, is one of 9 that started in 2023, is one of 30 observational ones, and was the 132nd registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

28 of the 154 studies in Carcinoma, Renal Cell with a site in Italy are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 154 studies in Carcinoma, Renal Cell with a site in Italy, or all of them as a file.
02

Study summary

The goal of this study is to comprehensively map intra and inter tumor heterogeneity of ccRCC in VHL patients through the use of imaging, molecular biology and genomics techniques.

Read the detailed description

It was hypothesized that the high intra- inter-tumor heterogeneity of sporadic ccRCC also defines VHL-ccRCCs, including different lesions within individual patients, and it was assumed that decoding VHL-ccRCC heterogeneity by coupling imaging, histology and molecular profiling of multiregional biopsies would help improve diagnostic tests and therapeutic choices for VHL patients.

In order to comprehensively map intra and inter tumor heterogeneity of ccRCC in VHL patients, the aims of the study are:

  1. To integrate pre-surgery imaging using conventional multiparametric MRI with tumor histology of geographical predeterminated multi-region biopsies in each ccRCC of VHL patients.
  2. To combine multiplex immunohistochemistry, bulk and single cell RNA sequencing and somatic mutations analysis with pan-tumor histological assessment.
  3. To optimize a protocol to generate VHL-ccRCC-derived tumor organoids (patient-derived organoids, PDO) and test anti tumor agents like HIF2alpha inhibitor in organoid cultures representative of intra- and inter-tumor heterogeneity.

This study will develop standardized models for diagnosis and molecular characterization of ccRCC in VHL disease using a combination of imaging, intrasurgical biopsying and multi-omics analysis. It will benefit of a clinical and research program devoted to VHL disease established at OSR in 2021 that centralizes Italian VHL patients. Since the current study relies on tumor biopsy techniques that are already established in clinical practice, the translational findings will be directly available and immediately affecting patients' care.

03

Conditions studied

  • Clear Cell Renal Cell Carcinoma
  • VHL Syndrome
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

VHL patients with at least 3 kidney tumors larger that 3cm to be surgically removed

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • VHL syndrome
  • Presence of at least 3 kidney tumors larger that 3cm to be surgically removed

Exclusion criteria

Exclusion Criteria:

  • Absence of VHL
  • Quantity of kidney tumors \< 3
  • Absence of surgery performance
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
3 participants (actual)
Target follow-up
1 Day
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • VHL patients

    Patients with hereditary Von Hippel-Lindau (VHL) with genetic diagnosis of VHL disease who have at least three tumors larger than 3cm that have to be surgically removed. The procedure involves standard surgery with the additional collection of 15ml of blood.

    Other: Blood collection

Interventions

  • OtherBlood collection

    15ml of blood are harvested before surgery

06

What researchers measure

Primary outcomes

  1. Integrating Imaging and multiregion biopsy sampling in VHL related ccRCC

    Pre-surgery imaging will be integrated using conventional multiparametric MRI with tumor histology of geographical predeterminated multi-region biopsies in each ccRCC of VHL patients.

    Time frame: From month 3 to month 20

  2. Determine immune and stromal heterogeneity in VHL-ccRCC

    Multiplex immunohistochemistry, bulk and single cell RNA sequencing and somatic mutations analysis with pan-tumor histological assessment will be combined.

    Time frame: DNAseq and bulk RNAseq will be carried out from month 7 until month 20. Multiplex immunohistochemistry (IHC) in multiregional biopsies and standard IHC on the whole tumors will be performed the last 12 months of the study.

  3. Generation and characterization of VHL-ccRCC patient-derived organoids

    A protocol to generate VHL-ccRCC-derived tumor organoids (patient-derived organoids, PDO) will be optimized to test anti tumor agents like HIF2alpha inhibitor in organoid cultures representative of intra- and inter-tumor heterogeneity.

    Time frame: From month 3 until the end of the project.

07

Study locations

1 site
  • IRCCS Ospedale San Raffaele
    Milan, MI 20132, Italy
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Jun 2025, 19 months.

Of 97 non-industry observational studies under Carcinoma, Renal Cell, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 241. This study's 19 months is below that.

Counting every sponsor, half of 139 studies reached it within 50 months; a quarter within 33 and three quarters within 94.

Primary completion moved once since we started tracking on Sep 25, 2026: May 2026 → Jun 2025, on Oct 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2023
First posted
Jan 8, 2024
StartActual
Nov 8, 2023
Primary completionActual
Jun 18, 2025was May 2026
CompletionActual
May 19, 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 16, 2026
Primary completion
May 19, 2026→Jun 18, 2025 (actual)
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Active, not recruiting→Completed
    Primary completion May 19, 2026→Jun 18, 2025 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06195150
Lead sponsor
IRCCS San Raffaele
Responsible party
Umberto Capitanio (Head of the Kidney Tumor Research Unit, IRCCS San Raffaele) — Principal investigator
First posted
Jan 8, 2024
Start date
Nov 8, 2023
Primary completion
Jun 18, 2025
Completion
May 19, 2026
Last update
Oct 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion